Clinical trials: Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT00095264
- Testing
- Darbepoetin Alfa
- Volunteers
- 209 people
- Sponsor
- Amgen
Leukemia, Myelodysplastic Syndrome
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a "phase I trial," in which a preset schedule of doses gets more powerful for each new group of patients as the…
- Trial name
- NCT00672165
- Testing
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Langerhans Cell Histiocytosis, Leukemia
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00008164
- Testing
- umbilical cord blood transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies how well daratumumab works in treating patients with acute myeloid leukemia that has come back or does not respond to treatment or high-risk myelodysplastic syndrome.
- Conditions
- High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03067571
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00301834
- Testing
- alemtuzumab, busulfan, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
MDS, Myelodysplastic Syndrome MDS
Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy
This is a single center phase II study of allogeneic stem cell transplantation in MDS who are unlikely to benefit from conventional therapy.
- Conditions
- MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome
- Trial name
- NCT07896928
- Testing
- Allogeneic Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ronald Paquette
Leukemia, Myelodysplastic Syndromes
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003336
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Myelodysplasia
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Patients with low-risk MDS verifying the eligibility criteria may be included in the study.
- Trial name
- LODEFI (NCT03387475)
- Testing
- Deferasirox
- Where
- France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Grenoble
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity.
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT07634536
- Testing
- VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: Ruxolitinib
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
- Trial name
- NCT03286530
- Testing
- Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
- Trial name
- NCT02848001
- Testing
- CC-90009
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 101 people
- Sponsor
- Celgene
Thalassemia, Sickle Cell Disease
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
The investigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2*< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and…
- Conditions
- Thalassemia, Sickle Cell Disease, Myelodysplasia
- Trial name
- SUFEMYO (NCT01911871)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Registry on Hypomethylating Agents in Myeloid Neoplasms
This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Trial name
- NCT01595295
- Testing
- non interventional
- Where
- 20 sites in Austria, Croatia
- Volunteers
- 1,500 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Acute Leukemia, Myelodysplastic Syndromes
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
This study will use droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma mutant allele frequency (MAF) in MDS and AML patients before, during and after chemotherapy treatment.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, AML, MDS
- Trial name
- iCare3 (NCT03138395)
- Testing
- droplet digital PCR
- Sponsor
- University of Florida
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
In this trial the investigators aim to evaluate safety and efficacy of combination Ivosidenib (AG-120) and nivolumab in the context of adult patients with Isocitrate dehydrogenase-1 (IDH1) mutated acute myeloid leukemias (AML) or…
- Trial name
- NCT04044209
- Testing
- AG-120, Nivolumab
- Where
- United States
- Sponsor
- Yale University
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
This study will assess the safety and efficacy of vismodegib in patients with relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).
- Trial name
- NCT01880437
- Testing
- cytarabine, vismodegib
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Bone Marrow Transplant Complications, Acute Myeloid Leukemia
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.
- Conditions
- Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes
- Trial name
- NCT05895201
- Testing
- Sitagliptin, Bortezomib, Cyclophosphamide
- Where
- United States
- Sponsor
- Indiana University
Myelodysplastic Syndrome
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are…
- Trial name
- NCT01751867
- Testing
- Decitabine at 15 mg/m2, Decitabine at 20 mg/m2
- Where
- 8 sites in China
- Volunteers
- 135 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Myelodysplastic Syndromes
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).
- Trial name
- NCT04797000
- Testing
- Eltrombopag
- Where
- 20 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.